BriaCell wins FDA clearance for Bria-PROS+ prostate cancer study
BriaCell Therapeutics has received a Study May Proceed letter from the US Food and Drug Administration, clearing its Investigational New Drug application for Bria-PROS+ and opening the way for a Phase 1/2a clinical study in prostate cancer. The Vancouver- and Philadelphia-headquartered company describes the candidate as a next-generation, personalised, off-the-shelf cell-based immunotherapy designed to activate multiple arms of the immune system simultaneously.
The IND clearance arrives roughly a year after BriaCell was awarded a $2 million non-dilutive grant from the US National Cancer Institute to fund manufacturing and clinical preparation for Bria-PROS+. That government backing provides a degree of non-dilutive runway for the study and offers a measure of external validation of the programme's scientific rationale.
The science behind Bria-PROS+
Preclinical data presented by the company at the American Association of Cancer Research annual meeting showed Bria-PROS+ activating both adaptive and innate immune pathways, including naïve T-cells, dendritic cells, and natural killer cells. BriaCell argues this multipronged mechanism may reduce the risk of immune escape, a common problem in tumour immunology where cancer cells evolve to evade single-target approaches.
The product builds on the same HLA-matching technology that underpins BriaCell's other personalised immunotherapy programmes. HLA matching seeks to improve immune activation by pairing patient tissue antigens to cell lines within the immunotherapy product, a design principle the company applies across its oncology portfolio. Whether this confers a meaningful clinical advantage over antigen-agnostic approaches remains to be demonstrated in patients.
Pipeline and competitive context
The Bria-PROS+ clearance extends a busy regulatory period for BriaCell. Its Bria-IMT programme is already in a Phase 3 pivotal trial for metastatic breast cancer, and Bria-BRES+, a related enhanced cell-based immunotherapy for breast cancer, received its own FDA IND clearance recently. The company also reported that the first patient dosed in the Bria-OTS breast cancer programme experienced sustained complete resolution of a lung metastasis, though BriaCell noted this as a single patient observation rather than a trial-level finding.
Prostate cancer immunotherapy is a competitive space. Sipuleucel-T, the dendritic cell therapy approved by the FDA in 2010, was the first therapeutic cancer vaccine to reach the market but achieved only modest commercial uptake. Since then, immune checkpoint inhibitors have shown limited efficacy in prostate cancer as a class, and the field has shifted attention toward combination strategies, targeted radiopharmaceuticals and next-generation androgen receptor inhibitors. BriaCell is positioning Bria-PROS+ as a cell-based alternative that can work alongside these approaches, though it has not yet disclosed planned combination regimens or the patient population it will enrol in Phase 1/2a.
William V. Williams, BriaCell's president and chief executive, said Bria-PROS+ is "designed to activate multiple components of the immune system," which the company believes could support meaningful therapeutic benefit with a favourable safety profile.
Near-term milestones for investors to watch include announcement of the trial's first patient dosing, publication of the full study protocol, and any interim safety signals from the dose-escalation portion of the Phase 1 cohort. Longer-dated catalysts include Phase 3 readout data from the Bria-IMT breast cancer programme, which would provide broader evidence for the platform's clinical utility.